Drug
Rmc 6291
Rmc 6291: highest development phase Phase 1/2, developed by Revolution Medicines. 2 trial records tracked on RxWires.
- Highest phase
- Phase 1/2
- Developer
- Revolution Medicines
Trials
| Drug | Phase | Indication |
|---|---|---|
| RMC-6291 NCT06162221 | Phase 1/2 | Non-Small Cell Lung Cancer, NSCLC |
| RMC-6291 NCT05462717 | Phase 1 | Non-Small Cell Lung Cancer (NSCLC) |
Latest
No recent events.
Follow Rmc 6291 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.